HCM City (VNS/VNA) – s and doctors exchanged new
approaches in the application of SGLT2 inhibitors in management of diabetes Type II at an online symposium held recently by the Ho Chi Minh City Diabetes
and Endocrinology Association and AstraZeneca.
SGLT2 inhibitor is a class of medications that inhibit the reabsorption of
glucose in the kidneys and therefore lower . s are
used in the treatment of Type II diabetes mellitus.
The symposium focused discussion on DECLARE clinical study, which clearly
reduced proteinuria progression on diabetes type 2 through medicine with SGLT2i
class. The new approach can help their kidneys revert to a healthy stage early.
“DECLARE has shown a specific effect in reducing renal complications in diabetic
patients, including patients with or without atherosclerotic cardiovascular
disease. The early screening of kidney diseases will help early intervention
and effective management of diabetes patients around the world – including Vietnam,
thereby helping to improve kidney and cardiovascular prognosis for the
patient,” said Dr. David Cherney from Toronto University, Canada.
With the participation of over 500 health professionals nationwide, the event
is part of activities to mark annual World Kidney Day on March 12.
Health experts also called for early detection and treatment of patients with
diabetes to minimise complications on hearts and kidneys. The introduction of a
new medication in SGLT2i class is positive news for the medical community and patients.
In Vietnam, the number of diabetes patients who have been treated and managed
by the health sector is still modest. The early prevention of complications on
kidneys, comprehensive protection of the kidney and heart of patients becomes
even more urgent to maintain a stable life and reduce their economic burden
later.
The health sector estimated that Vietnam has around 3.8 million diabetes
patients, making up 6 percent of the country’s adult population./.
Source: VietnamPlus